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Abstract





symptoms compatible with gastroparesis were prospectively included between 2014 
and	2018.	Patients	were	simultaneously	examined	with	GES	and	WMC.	Symptoms	
were	 assessed	 with	 the	 Patient	 Assessment	 of	 Upper	 Gastrointestinal	 Symptom	
Severity	Index	(PAGI-SYM)	questionnaire.	All	patients	were	on	intravenous	glucose-
insulin infusion during testing.
Key Results: WMC	and	GES	correlated	r = .74, P	<	 .001.	Compared	to	GES,	WMC	
at	ordinary	cutoff	for	delayed	GE	(300	minutes)	had	a	sensitivity	of	0.92,	specificity	
0.73, accuracy 0.80, and Cohen's kappa κ = 0.61 (P	<	 .001).	By	 receiver	operating	
characteristics	(ROC),	the	area	under	the	curve	was	0.95	(P	<	.001).	A	cutoff	value	for	
delayed	GE	of	385	minutes	produced	sensitivity	0.92,	specificity	0.83,	accuracy	0.86,	
and Cohen's kappa κ = 0.72 (P	<	.001).	Inter-rater	reliability	for	GE	time	with	WMC	
was r = .996, κ = 0.97, both P < .001. There was no difference in symptom severity 
between	patients	with	normal	and	delayed	GE.
Conclusions & Inferences: Our findings demonstrate the applicability of WMC as a 
reliable test to assess gastric emptying in diabetic gastroparesis showing very high 
inter-observer	correlation.	By	elevating	the	cutoff	value	for	delayed	emptying	from	
300	to	385	minutes,	we	found	higher	specificity	without	reducing	sensitivity.
K E Y W O R D S
diabetes mellitus, gastric emptying, gastric emptying scintigraphy, gastroparesis, wireless 
motility capsule
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1  | INTRODUC TION
Diabetic gastroparesis is a condition characterized by upper gastro-
intestinal	(GI)	symptoms	and	delayed	gastric	emptying	(GE)	without	
gastric outlet obstruction.1 In addition to potentially debilitating 
symptoms of nausea, vomiting and upper abdominal pain, the condi-
tion may have profound implications for the patients’ ability to regu-
late their blood glucose levels.2,3	Delayed	GE	is	associated	with	both	
short-	and	long-term	hyperglycemia.4 Gastroparesis may also influ-
ence the absorption of oral medications, emphasizing the need for 
reliable,	inexpensive,	and	accessible	tests	for	measuring	GE.5
Gastric	 emptying	 scintigraphy	 (GES)	 has	 long	 been	 consid-
ered	gold	 standard	 for	evaluating	GE	 in	both	 research	and	clinical	
practice.6	By	 radiolabeling	a	 liquid	or	solid	meal	and	tracking	 it	by	
a	 gamma	 camera,	 the	 method	 gives	 a	 physiological,	 quantitative	
measurement	of	GE.7 Unfortunately, a number of local variants of 
the	test	exist,	both	in	terms	of	meal	composition,	and	duration	and	
frequency	of	imaging.6,8 The radiation dosage also limits its applica-
bility in certain patient groups.9 Moreover, the availability of gamma 
cameras	is	reduced,	in	part	due	to	high	acquisition	costs.
The	 wireless	 motility	 capsule	 (WMC;	 SmartPill,	 Medtronic)	
measures pH, pressure, and temperature throughout the GI tract, 
thereby	 providing	 the	 means	 for	 calculating	 GE.10 WMC has 
since	 2009	 been	 approved	 by	 The	 United	 States	 Food	 and	 Drug	
Administration for the investigation of suspected gastroparesis and 
has in previous studies shown good agreement with scintigraphy.8,11 
However,	there	are	few	studies	validating	WMC	against	GES,	high-
lighting the need for further research. To our knowledge, this is the 
first	European	study	comparing	the	two	methods	in	a	cohort	of	dia-
betes patients with suspected gastroparesis.




ary aim was to identify proportions with rapid, normal, and delayed 
gastric emptying by the two methods. We also aimed to illuminate 
why some patients presented inconsistent test results (one positive/
one	negative),	by	comparing	with	those	showing	delayed	emptying	
on	both	tests.	Finally,	we	wanted	to	compare	symptom	severity	be-
tween patients with rapid, normal, and delayed gastric emptying.
2  | MATERIAL S AND METHODS
2.1 | Study population
Seventy-two	patients	 (49	women)	with	diabetes	mellitus	 (DM)	and	




with upper endoscopy to rule out obstructing lesions or other pa-
thology	 explaining	 their	 symptoms.	 Patients	 under	 18	 years	 of	
age and pregnant or breastfeeding women were not included in 
the	 study.	During	 examinations,	 all	 patients	were	 admitted	 to	 the	
hospital	where	 they,	 in	 addition	 to	 tests	 and	 questionnaires,	 gave	
blood	samples	and	were	interviewed	and	examined	by	a	physician.	
Medications potentially altering GI motility were paused in advance 
and during the study: proton pump inhibitors (seven days in ad-
vance),	 histamine	H2-receptor	 antagonists,	 opioid	 analgesics,	 non-
steroidal	 anti-inflammatory	 drugs,	 antidiarrheal	 drugs,	 prokinetic	





a standardized 260 kilocalorie (kcal; 66% carbohydrate, 17% protein, 
2%	 fat,	 3%	 fiber)	 nutrient	bar	 (SmartBar,	Medtronic),	 and	a	boiled	
egg	 (90	 kcal;	 1.1%	 carbohydrate,	 13%	 protein,	 11%	 fat,	 0%	 fiber)	
radiolabeled	with	Tc-99m-nanocolloid.12 Then, the WMC was swal-
lowed, and scintigraphic imaging commenced immediately after-
ward. During the meal, patients could drink 120 mL of water. After 
swallowing	the	WMC,	they	fasted	for	another	six	hours,	but	were	al-




glucose if they fell below 4 mmol/L.
2.2.1 | Gastric emptying scintigraphy
Simultaneous anterior and posterior planar scintigraphy of the 
upper	abdomen	(1	minute	per	view)	were	performed	on	a	double-
headed	 camera	 system	 (Siemens	 e.cam;	 Siemens	 Healthineers).	
Pictures	were	 taken	 at	 0,	 30	minutes,	 1,	 2,	 3,	 and	4	 hours	 in	 ac-
cordance with current guidelines.13	 Images	were	quantified	 using	
Segami	Oasis	1.9.4.9	(Segami	Corp.,	Inc)	by	drawing	a	region	of	in-
terest around the outline of the stomach at 0 minutes, which was 
Key Points
• Gastroparesis is an important complication of diabetes 
mellitus, and detecting delayed gastric emptying is cur-
rently mandatory for establishing the diagnosis.
•	 Examining	gastric	emptying	in	a	cohort	of	symptomatic	
diabetes patients, wireless motility capsule showed sub-
stantial agreement with scintigraphy.
• We found no differences in symptom severity between 
patients with normal and delayed gastric emptying by 
any of the tests.
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then	 copied	 onto	 images	 taken	 at	 other	 time-points	 (Figure	 1).	
Gastric	 retention	was	 quantified	 as	 the	 root	mean	 square	 of	 the	








taining sensors for pH, temperature and pressure, a battery and a 
transmitter.10,15 After activation, it transmits data to a portable re-
ceiver, which the patient carries close to the body during the entire 
examination.15 Our patients were instructed to return the receiver 
after	5	days,	whereupon	data	were	downloaded	to	a	personal	com-
puter using a USB docking device.
WMC transit times were calculated using MotiliGI software 
(Medtronic).	WMC	gastric	emptying	time	(WMC	GET)	was	defined	
as the time between capsule ingestion and passage through the py-
lorus,	as	marked	by	a	rapid	rise	of	>3	pH	units	(Figure	1).	Delayed	
WMC	GET	is	defined	as	>300	minutes	(5	hours),	severely	delayed	








Scanner	 PE	 (Biocom	 Technologies).	 The	 system	 investigates	 both	
time	and	frequency	domain	parameters,	and	has	been	described	and	
validated in detail elsewhere.18 All recordings were performed in a 
fasting state by the same trained technician. The HRV recordings 






Patient	 Assessment	 of	 Upper	 Gastrointestinal	 Symptom	 Severity	
Index	 (PAGI-SYM).19	 PAGI-SYM	 can	 be	 grouped	 into	 six	 subsets	
(Table	4),	where	the	average	of	subset	1-3	make	up	the	Gastroparesis	
Cardinal	Symptom	Index	(GCSI).20
TA B L E  1   Clinical characteristics
Variables Results








Diabetes duration, y 27	(22)













































between continuous variables. Differences between groups were 




positive and negative predictive values, accuracy, positive and nega-
tive likelihood ratios, Cohen's kappa measure of agreement, and a 
receiver	operating	characteristics	(ROC)	curve.	To	find	the	optimal	
cutoff	value	for	GE	by	WMC,	we	calculated	the	maximum	Youden's	
F I G U R E  1  GES	(top)	and	WMC	results	
from a patient with diabetic gastroparesis. 















































































values) Median (IQR) Rapid Normal Delayed
GES	(%	retention)
GES	30	min	(>70) 91	(13) 7	(10.0%) 63	(90.0%) –
GES	1	hour	(30	-	90) 75	(28) 3	(4.2%) 53	(74.6%) 15	(21.1%)
GES	2	hours	(<60) 35	(41) – 51	(71.8%) 20	(28.2%)
GES	3	hours	(<30) 15	(34) – 47	(66.2%) 24	(33.8%)
GES	4	hours	(<10) 5	(19) – 43	(60.6%) 28	(39.4%)
WMC	(min)




range; WMC, wireless motility capsule.
TA B L E  2  Gastric	emptying	by	GES	and	
WMC
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index.	 P	 ≤	 .05	was	 defined	 as	 the	 level	 of	 statistical	 significance.	














to pause of medication, no other test related adverse events were 
reported during the study.
3.1 | Diagnostic test comparison






Inter-rater	 correlation	 for	 identifying	WMC	GET	 between	 the	
two	examiners	was	 r = .996, while agreement was Cohen's kappa 
κ	=	.97	(95%	CI	0.90-1.00),	both	P < .001. MotiliGI calculated WMC 
GET	 in	 51	 patients	 (75.0%).	 Correlation	 between	 examiner	 1	 and	
MotiliGI was r = .967, Cohen's kappa κ	=	.96	(95%	CI	0.88-1.00),	both	
P	<	.001.	Correlation	between	examiner	2	and	MotiliGI	was	r	=	.965	
and agreement κ	=	.92	(95%	CI	0.81-1.00),	both	P < .001.




tients	 (39.4%)	with	4-hour	GES,	χ2	 (1)	=	23.86,	P < .001. With the 
385	minutes	 cutoff	 value,	 31	 patients	 (46.3%)	 had	 delayed	WMC	
GET,	compared	to	4-hour	GES,	χ2	(1)	=	32.21,	P	<	.001.	Twenty-seven	
(40.3%)	 had	 severely	 delayed	WMC	GET,	 compared	 to	10	 (14.1%)	
with	GES,	χ2	(1)	=	9.48,	P	<	.01.	Severe	retention	by	WMC	and	4-hour	




(T2DM),	it	was	229	minutes	(155	minutes),	P = .01. Using the ordi-
nary	300	minutes	cutoff	value,	32	out	of	55	(58%)	T1DM	patients	
had	delayed	WMC	GET;	the	same	proportion	in	T2DM	was	3	out	
of	 12	 (25%),	χ2	 (1)	 =	3.12,	P	 =	 .08.	With	 the	385	minutes	 cutoff	
value,	31	(56%)	with	T1DM	and	0	with	T2DM	had	delayed	GE,	χ2 
(1)	=	10.42,	P	<	.01.	Median	retention	at	4-hour	GES	was	8%	(22%)	





GET,	 while	 11	 (17%)	 had	 normal	 GES	 and	 delayed	 WMC	 GET.	
Only	two	patients	 (3%)	had	delayed	GES	and	normal	WMC	GET,	
this group being too small for further statistical comparisons. In 
Table 4, we have compared selected clinical characteristics, symp-
tom scores, gastric emptying test results, blood glucose values, 
and	heart	 rate	 variability	 parameters	 (HRV)	between	 those	with	
consistent	GE	test	results	(both	tests	delayed;	true	positives)	and	
those	 with	 inconsistent	 results	 (normal	 GES	 and	 delayed	WMC	
GET;	false	positives).
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3.3 | Symptom scores
Table	5	contains	results	for	GCSI,	PAGI-SYM,	and	all	subsets,	 in-
cluding a comparison between patients with normal and delayed 
GE	by	WMC	(300	minutes	cutoff)	and	GES	at	4	hours.	We	found	
no difference between patients with normal and delayed emptying 
at	any	WMC	GET	cutoff	values	or	GES	time-points,	both	looking	
at each diabetes type separately and all patients combined. There 
was no difference in symptom severity between patients with 




there was no difference in symptom severity between patients 
with T1DM and T2DM.
4  | DISCUSSION
In	this	prospective	study,	we	aimed	to	validate	WMC	against	GES	in	
a patient cohort with DM and symptoms compatible with gastropa-
resis.	We	found	a	strong	correlation	between	WMC	and	4-hour	GES,	
r = .74 (P	<	 .001).	With	 the	standard	cutoff	value	of	300	minutes,	
both	sensitivity	 (0.92)	and	specificity	 (0.73)	for	 identifying	delayed	
GE	were	high,	and	the	two	methods	showed	substantial	agreement	
demonstrated by Cohen's kappa κ = .61 (P	<	.001).	These	results	are	
similar	to	previous	studies	comparing	WMC	and	GES,	where	Kuo	et	
al	found	a	correlation	between	WMC	GET	and	4-hour	GES	of	r = .73 
and Lee et al found a device agreement of κ = .61 in the diabetes sub-
group.8,11 However, in the latter study overall agreement was only 
moderate when also including patients without DM. In comparison 
with other methods for determining gastric emptying, WMC has a 
similar diagnostic accuracy to 13carbon-labeled	 gastric	 emptying	
breath	tests	for	solids	(GEBT)	and	is	far	superior	to	gastric	emptying	
of	radiopaque	markers	(ROMs).21,22 Other methods have not gained 
widespread usage outside research settings.16
We	 also	 found	 a	 near	 perfect	 inter-rater	 correlation	 (r = .996, 
P	<	.001)	and	Cohen's	kappa	(κ = .97, P	<	.001)	for	identifying	WMC	
GET.	For	the	evaluation	of	delayed	GE,	our	findings	indicate	a	high	
diagnostic accuracy of WMC, with interpretation of results being 
examiner	independent.	Interestingly,	the	correlations	between	each	
examiner	 and	 the	MotiliGI	 software	 for	estimating	GET	were	also	
very	strong.	However,	in	as	many	as	25%	of	tests	the	software	did	
not	manage	 to	calculate	GET,	 compared	 to	 the	one	patient	where	
manual analysis failed to make an estimation. Until further refine-
ment of the software, manual test analysis is therefore essential.
Current normative transit time values for WMC are based on a 
study	by	Wang	et	al,	examining	215	healthy,	asymptomatic	volun-
teers.10	To	 identify	 the	optimal	cutoff	value	 for	delayed	GE	 in	our	
symptomatic DM cohort, we used ROC curve coordinates to find 
the	maximum	Youden's	index.	A	value	of	385	minutes	increased	the	
specificity to 0.83 without reducing sensitivity. Cohen's kappa was 
also increased to κ = .72 (P	<	.001).	Consequently,	by	elevating	the	
cutoff value, the risk of identifying false positives is reduced. One 
might therefore argue for the establishment of separate cutoff val-
ues for symptomatic diabetes patients, although we recommend fur-
ther	follow-up	studies	to	confirm	our	findings.
At both cutoff values, a larger proportion of patients had delayed 
GE	by	WMC	than	GES.	Lee	et	al	propose	a	reasonable	explanation	
for this discrepancy in the different physiological mechanisms used 
by	the	two	tests:	While	GES	examines	the	emptying	of	a	gradually	
dissolving	 solid	 meal,	 the	 indigestible	WMC	 is	 expelled	 from	 the	





















F I G U R E  3  ROC	curve	for	WMC	GET	compared	to	4-hour	
GES	showing	an	AUC	of	0.95	(P	<	.001,	95%	CI	0.89-1.00).	
Abbreviations: ROC, receiver operating characteristics. WMC, 
wireless	motility	capsule.	GET,	gastric	emptying	time.	GES,	gastric	
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stomach	by	the	returning	phase	III	of	the	migrating	motor	complex	
(MMC).	In	addition	to	measuring	GE,	the	WMC	may	therefore	also	
measure impairment of the MMC and dyscoordination of gastric and 
small bowel motility, leading the authors to argue that the WMC in 
fact	 has	 higher	 sensitivity	 for	 detecting	 gastroparesis	 than	GES.11 
Indeed,	 passage	of	 the	WMC	does	 not	 occur	 before	>90%	of	 the	
meal has emptied.8	As	underlined	by	Kloetzer	et	al,	WMC	is	there-
fore	able	to	provide	information	about	both	gastric	fasting	and	fed-
state.17 Interestingly, doing subgroup analyses, Lee et al found the 
same proportions with delayed emptying by both tests in diabetes 
patients.11 The overall difference in their study was thus driven by 
the	higher	proportion	with	delayed	emptying	by	WMC	in	the	non-di-
abetic group.11 To better understand the discrepancies in test results 
between	 the	 two	methods,	we	 compared	patients	with	 false-pos-




longer in the true positive group. This finding further bolsters the 
argument for increasing the cutoff value for delayed emptying in di-
abetes patients.
Wireless motility capsule also identified a higher proportion of 
patients	with	 severe	 retention	 than	GES.	 In	 this	 respect,	we	 only	
found a fair agreement between the two methods (κ = .34, P	<	.001),	
similar to previous studies.11	 The	 most	 likely	 explanation	 is	 that	
definite	cutoff	values	 for	severely	delayed	GET	are	not	clearly	es-
tablished. WMC failed to identify any patients with rapid gastric 
emptying,	while	GES	 found	 three	 (4.2%)	 and	 seven	 (10.0%)	 at	 the	
60	and	30	minutes	time-points,	respectively.	Previous	studies	also	
found	a	higher	share	with	rapid	GE	using	GES.11 Still, given that 20% 
of	symptomatic	diabetes	patients	may	have	rapid	GE,	it	was	surpris-
ing that we did not identify any cases using WMC.23 Interestingly, 
the	prevalence	with	delayed	GE	increased	at	each	GES	time	point.	
This underlines the importance of following the recommended 
protocol	of	taking	pictures	until	 four	hours	to	avoid	false-negative	
tests.6,14
Previous	 studies	 comparing	 the	 symptom	 severity	 between	
patients	with	normal	and	delayed	GE	have	shown	inconsistent	re-
sults.24-26	In	this	study,	we	found	no	difference	in	PAGI-SYM,	GCSI	
or any of their subsets between patients with normal and delayed 
GE.	Neither	did	we	find	any	differences	comparing	patients	with	
normal	and	rapid	emptying.	This	 lack	of	association	between	GE	
and	patient-reported	 symptoms	 is	one	of	 the	main	 challenges	 in	
the	field	of	gastroparesis	research.	The	explanation	is	 likely	mul-
tifactorial.	Firstly,	patients	with	suspected	diabetic	gastroparesis	
often present a diversity of unspecific symptoms, not only limited 
to cardinal symptoms of nausea, vomiting, early satiety, fullness, 
and	bloating,	but	often	also	abdominal	pain,	reflux,	diarrhea,	con-
stipation, and fecal incontinence.27-30 Adding to the confusion, 
delayed	GE	is	present	in	30%-50%	with	longstanding	diabetes	re-
gardless	 of	 symptoms,	 probably	 as	 a	 consequence	of	 autonomic	
neuropathy.5,31-33 Secondly, there are multiple pathophysiological 
alterations associated with diabetic gastroparesis, both locally in 
the gut and in the autonomic and central nervous system. 28 Some 
of these, like the loss of interstitial Cells of Cajal, can be directly 
linked	to	the	development	of	delayed	GE.34	Others	may	explain	the	
genesis of gastrointestinal symptoms through different mecha-
nisms, like abnormal central neuronal activity.35,36 Although mostly 















BMI, kg/m2 25.1	(7.9) 23.1	(6.1) .27
Symptom scores














GCSI 2.2	(2.1) 2.9	(1.6) .74
PAGI-SYM	(total) 2.9	(2.2) 2.6	(1.3) .64
Gastric emptying tests
GES	4	hours,	% 5	(4) 26	(36) <.001





HbA1c, mmol/mol 62	(11) 72	(37) .09
Heart rate variability
Mean HR at rest, 
BPM
79.8	(19.1) 79.3	(23.1) .98
SDNN,	ms 23.8	(20.7) 17.6	(12.6) .92
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controlled	for	in	studies,	the	influence	of	medication	side-effects	
and other comorbidities on gastrointestinal symptoms, can also be 
a	confounder.	Finally,	more	than	a	quarter	of	patients	with	func-
tional dyspepsia, a highly prevalent condition with symptoms mim-
icking	gastroparesis	also	present	with	delayed	GE.24 An important 
goal for future gastroparesis studies must therefore be to identify 
other	biomarkers	better	correlated	to	patient-reported	symptoms.	
By	 expanding	 focus	 beyond	 the	 pylorus,	 recent	 studies	 have	 in-
deed uncovered a possible link between small bowel dysmotility 
and symptoms suggestive of gastroparesis.37-39 Here, the WMC 
may play an important role in further research, providing pH and 
pressure profiles from gut segments otherwise largely unavailable 
for	examination.5,40,41
Nevertheless,	 as	 the	 rate	 of	 GE	 is	 pivotal	 in	 determining	
postprandial glycaemia, its measurement will still be of great im-
portance in diabetes patients, especially those presenting with 
unexplained	 fluctuations	 in	blood	glucose	 levels.3	Consequently,	
the latest consensus statement on investigation of gastric motility 
recommends	GE	studies	to	be	performed	in	patients	with	poorly	
controlled diabetes.42	Furthermore,	as	clinical	presentation	alone	
can rarely differentiate between rapid and delayed emptying, it is 
recommended	 to	determine	GE	 in	patients	with	 symptoms	com-
patible with gastroparesis, where upper GI endoscopy has not 





during the same test. This is especially relevant in diabetes patients, 
often presenting multiregional dysmotility.5,44	In	contrast	to	GES,	it	
does not involve radiation and has a universally standardized meal.45 
Furthermore,	conduction	of	 the	test	 requires	 little	 training,	 transit	
time	 results	 are	mostly	 easy	 to	 interpret,	 and	 the	 test	 equipment	
is not space consuming. It may therefore be suitable for regular 
out-patient	 clinics,	 although	 its	 availability	 is	 so	 far	mostly	 limited	
to tertiary centers.46	Costs	are	comparable	to	GES,	both	tests	being	
more	expensive	 than	GEBT	and	ROMs.16,22 However, unlike other 
GE	tests,	where	patients	need	to	stay	in	the	clinic	for	at	least	half	a	
workday, commencing WMC testing rarely takes more than 30 min-
utes.	 During	 the	 rest	 of	 the	 examination,	 patients	 are	 ambulant.	
Consequently,	 the	 associated	 loss	 of	 productivity	 is	 less	 for	 both	
patients and clinicians.
There are some limitations to our study. To make the WMC pro-
tocol most similar to clinical practice, we used the standardized ce-
real bar supplied by the producer. To be able to perform the two 
GE	tests	simultaneously,	we	had	to	serve	a	radiolabeled	egg	as	an	
addendum. This increased the total energy content of the meal by 
approximately	90	kcal.	Higher	calorie	meals	are	expected	to	empty	
more slowly from the stomach, potentially increasing the proportion 
of	patients	with	delayed	GE.	Furthermore,	our	cohort	had	a	predom-
inance	of	women	and	patients	with	Type	1	DM	(Table	2).	The	gender	
distribution of gastroparesis between women and men is 4:1, while 
the cumulative incidence of gastroparesis is higher in Type 1 DM.47 
Still, the higher prevalence of Type 2 DM in the society makes this 
group underrepresented in the study population. While evaluating 
the	WMC	test's	inter-rater	reliability,	we	unfortunately	did	not	per-
form	 an	 inter-observer	 agreement	 evaluation	 of	 GES.	 Finally,	 the	
study was conducted at a tertiary center receiving referrals from 
secondary healthcare institutions. Accordingly, our patient cohort 
may be more severely affected by their disease than diabetes pa-
tients treated in primary care.
A strength of the study was its prospective design and 
the	 simultaneous	 assessments	 with	 WMC	 and	 GES,	 thereby	
avoiding	 intra-individual	 variations	 in	 GE.	 During	 the	 study,	 all	
patients were admitted to the hospital, where they were on in-
travenous	 glucose-insulin	 infusion	 during	 both	 fasting	 and	 test-
ing.	 Consequently,	 we	 were	 able	 to	 avoid	 major	 fluctuations	 in	
blood	sugar	 levels	potentially	affecting	GE,	as	well	as	preventing	
TA B L E  5  Symptom	scores	and	gastric	emptying	by	GES	and	WMC
Variables All patients
GES 4 hours WMC GET 300 min
Normal Delayed P-value Normal Delayed P-value
PAGI-SYM
1)	Nausea/vomiting 1.7	(2.3) 1.7	(2.1) 2.0	(2.0) .37 1.3	(2.1) 2.0	(2.0) .49
2)	Fullness/early	satiety 3.3	(1.8) 3.0	(1.75) 3.25	(1.5) .39 3.3	(1.5) 3.3	(2.0) .72
3)	Bloating 3.4	(2.4) 3.5	(2.5) 3.0	(2.5) .73 3.8	(2.4) 3.0	(2.5) .95
4)	Upper	abdominal	pain 3.0	(2.5) 3.5	(2.5) 3.0	(2.0) .39 3.5	(2.0) 3.0	(2.5) .32
5)	Lower	abdominal	pain 2.5	(2.5) 3.0	(3.5) 2.0	(2.0) .65 2.0	(3.3) 3.0	(2.0) .26
6)	Heartburn/regurgitation 1.6	(2.3) 2.3	(2.6) 1.4	(1.7) .18 2.5	(2.6) 1.6	(1.7) .30
GCSI 2.8	(1.5) 2.8	(1.6) 2.7	(1.3) .72 2.9	(1.7) 2.8	(1.9) .69
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iatrogenic	hypoglycemia.	Finally,	our	study	is	the	largest	prospec-
tive study validating the WMC in DM patients, increasing the ro-
bustness of our results.




racy further, possibly implying the need for separate cutoff values in 
symptomatic diabetes patients.
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